## Alex S Evers

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2558340/publications.pdf

Version: 2024-02-01

117625 71685 6,144 173 34 76 citations h-index g-index papers 182 182 182 5036 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Neurosteroid Modulation of GABA <sub>A</sub> Receptor Function by Independent Action at Multiple Specific Binding Sites. Current Neuropharmacology, 2022, 20, 886-890.	2.9	2
2	Roles for Anesthesiologists in the Future of Medicine in the United States. Anesthesia and Analgesia, 2022, 134, 231-233.	2.2	2
3	Intrasubunit and intersubunit steroid binding sites independently and additively mediate $\hat{l}\pm 1\hat{l}^22\hat{l}^32L$ GABA <sub>A</sub> receptor potentiation by the endogenous neurosteroid allopregnanolone. Molecular Pharmacology, 2021, 100, MOLPHARM-AR-2021-000268.	2.3	10
4	Validation of Trifluoromethylphenyl Diazirine Cholesterol Analogues As Cholesterol Mimetics and Photolabeling Reagents. ACS Chemical Biology, 2021, 16, 1493-1507.	3.4	9
5	Anaesthetic-induced developmental neurotoxicity on (neuro)steroids. British Journal of Anaesthesia, 2021, 126, 34-37.	3.4	2
6	Perspective on the relationship between GABAA receptor activity and the apparent potency of an inhibitor. Current Neuropharmacology, 2021, $19$ , .	2.9	4
7	Reduced Activation of the Synaptic-Type GABA <sub>A</sub> Receptor Following Prolonged Exposure to Low Concentrations of Agonists: Relationship between Tonic Activity and Desensitization. Molecular Pharmacology, 2020, 98, 762-769.	2.3	2
8	Analysis of Modulation of the II GABAA Receptor by Combinations of Inhibitory and Potentiating Neurosteroids Reveals Shared and Distinct Binding Sites. Molecular Pharmacology, 2020, 98, 280-291.	2.3	2
9	Enhancement of muscimol binding and gating by allosteric modulators of the GABAA receptor: relating occupancy to state functions. Molecular Pharmacology, 2020, 98, MOLPHARM-AR-2020-000066.	2.3	8
10	Enhancement of Muscimol Binding and Gating by Allosteric Modulators of the GABA <sub>A</sub> Receptor: Relating Occupancy to State Functions. Molecular Pharmacology, 2020, 98, 303-313.	2.3	6
11	Site-specific effects of neurosteroids on GABAA receptor activation and desensitization. ELife, 2020, 9,	6.0	32
12	Protocol for a proof-of-concept observational study evaluating the potential utility and acceptability of a telemedicine solution for the post-anesthesia care unit. F1000Research, 2020, 9, 1261.	1.6	2
13	Multiple neurosteroid and cholesterol binding sites in voltage-dependent anion channel-1 determined by photo-affinity labeling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1269-1279.	2.4	26
14	The molecular determinants of neurosteroid binding in the GABA(A) receptor. Journal of Steroid Biochemistry and Molecular Biology, 2019, 192, 105383.	2.5	14
15	Multiple functional neurosteroid binding sites on GABAA receptors. PLoS Biology, 2019, 17, e3000157.	5.6	76
16	Common binding sites for cholesterol and neurosteroids on a pentameric ligand-gated ion channel. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 128-136.	2.4	18
17	Mapping two neurosteroid-modulatory sites in the prototypic pentameric ligand-gated ion channel GLIC. Journal of Biological Chemistry, 2018, 293, 3013-3027.	3.4	28
18	High Constitutive Activity Accounts for the Combination of Enhanced Direct Activation and Reduced Potentiation in Mutated GABAA Receptors. Molecular Pharmacology, 2018, 93, 468-476.	2.3	5

#	Article	IF	CITATIONS
19	SmartTots Update Regarding Anesthetic Neurotoxicity in the Developing Brain. Anesthesia and Analgesia, 2018, 126, 1393-1396.	2.2	40
20	Beverley A. Orser, M.D., Ph.D., F.R.C.P.C., F.C.A.H.S., Recipient of the 2018 Excellence in Research Award. Anesthesiology, 2018, 129, 644-645.	2.5	0
21	Enhanced GABAergic actions resulting from the coapplication of the steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam. Scientific Reports, 2018, 8, 10341.	3.3	26
22	Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins. Analytical Chemistry, 2017, 89, 2636-2644.	6.5	20
23	Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1. Journal of Biological Chemistry, 2017, 292, 9294-9304.	3.4	54
24	Anesthetic Neurotoxicity: New Findings and Future Directions. Journal of Pediatrics, 2017, 181, 279-285.	1.8	20
25	Persistent Postoperative Cognitive Decline?. Anesthesiology, 2016, 124, A23-A23.	2.5	2
26	The GAS trial. Lancet, The, 2016, 387, 1613-1614.	13.7	0
27	The Fallacy of Persistent Postoperative Cognitive Decline. Anesthesiology, 2016, 124, 255-258.	2.5	52
28	Activation and modulation of recombinant glycine and GABA <sub>A</sub> receptors by 4â€halogenated analogues of propofol. British Journal of Pharmacology, 2016, 173, 3110-3120.	5.4	19
29	In Reply. Anesthesiology, 2016, 125, 428-429.	2.5	0
30	Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol. Current Neuropharmacology, 2016, 14, 772-780.	2.9	37
31	Anesthetic Neurotoxicity — Clinical Implications of Animal Models. New England Journal of Medicine, 2015, 372, 796-797.	27.0	283
32	Mutational Analysis of the Putative High-Affinity Propofol Binding Site in Human $\langle i \rangle \hat{l}^2 \langle i \rangle 3$ Homomeric GABA $\langle sub \rangle A \langle sub \rangle$ Receptors. Molecular Pharmacology, 2015, 88, 736-745.	2.3	20
33	Neurosteroid Analogues. 18. Structure–Activity Studies of <i>ent</i> -Steroid Potentiators of γ-Aminobutyric Acid Type A Receptors and Comparison of Their Activities with Those of Alphaxalone and Allopregnanolone. Journal of Medicinal Chemistry, 2014, 57, 171-190.	6.4	28
34	11-trifluoromethyl-phenyldiazirinyl neurosteroid analogues: potent general anesthetics and photolabeling reagents for GABAA receptors. Psychopharmacology, 2014, 231, 3479-3491.	3.1	12
35	Principles of drug biotransformation. , 2013, , 72-89.		1
36	Pharmacodynamic drug interactions in anesthesia. , 2013, , 147-165.		2

#	Article	IF	CITATIONS
37	Pharmacokinetics of inhaled anesthetics. , 2013, , 385-396.		2
38	Clinical pharmacology of intravenous anesthetics. , 2013, , 444-465.		3
39	Antimotility and antisecretory drugs. , 2013, , 842-854.		О
40	Drugs affecting coagulation and platelet function. , 2013, , 912-947.		0
41	Drug allergy and treatment. , 2013, , 1117-1127.		0
42	Bronchodilators., 2013,, 751-766.		1
43	A propofol binding site on mammalian GABAA receptors identified by photolabeling. Nature Chemical Biology, 2013, 9, 715-720.	8.0	199
44	Increased Risk of Intraoperative Awareness in Patients with a History of Awareness. Anesthesiology, 2013, 119, 1275-1283.	2.5	53
45	In Reply. Anesthesiology, 2013, 118, 759-760.	2.5	0
46	Deep Amino Acid Sequencing of Native Brain GABAA Receptors Using High-Resolution Mass Spectrometry. Molecular and Cellular Proteomics, 2012, 11, M111.011445.	3.8	135
47	Perspective. Academic Medicine, 2012, 87, 348-355.	1.6	7
48	Neurosteroid Analog Photolabeling of a Site in the Third Transmembrane Domain of the $\hat{l}^2$ 3 Subunit of the GABA <sub>A</sub> Receptor. Molecular Pharmacology, 2012, 82, 408-419.	2.3	69
49	Characteristics of concatemeric GABA $<$ sub $>$ A $<$ /sub $>$ receptors containing $\hat{l}\pm 4 \hat{l}'$ subunits expressed in $<$ i $>X$ enopus $<$ /i $> oocytes$ . British Journal of Pharmacology, 2012, 165, 2228-2243.	5.4	43
50	Neurosteroid Analogues. 17. Inverted Binding Orientations of Androsterone Enantiomers at the Steroid Potentiation Site on $\hat{I}^3$ -Aminobutyric Acid Type A Receptors. Journal of Medicinal Chemistry, 2012, 55, 1334-1345.	6.4	20
51	A neurosteroid analogue photolabeling reagent labels the colchicineâ€binding site on tubulin: A mass spectrometric analysis. Electrophoresis, 2012, 33, 666-674.	2.4	16
52	Ketamine-induced Neuroapoptosis in the Fetal and Neonatal Rhesus Macaque Brain. Anesthesiology, 2012, 116, 372-384.	2.5	387
53	What Are We Looking For?. Anesthesiology, 2012, 117, 230-231.	2.5	11
54	Neurosteroid Analogues. 16. A New Explanation for the Lack of Anesthetic Effects of î" <sup>16</sup> -Alphaxalone and Identification of a î" <sup>17(20)</sup> Analogue with Potent Anesthetic Activity. Journal of Medicinal Chemistry, 2011, 54, 3926-3934.	6.4	5

#	Article	IF	Citations
55	Review of Clinical Evidence for Persistent Cognitive Decline or Incident Dementia Attributable to Surgery or General Anesthesia. Journal of Alzheimer's Disease, 2011, 24, 201-216.	2.6	110
56	Prevention of Intraoperative Awareness in a High-Risk Surgical Population. New England Journal of Medicine, 2011, 365, 591-600.	27.0	479
57	Congratulations from the IARS!. Anesthesiology, 2011, 115, 679-680.	2.5	1
58	Relationship between Bispectral Index Values and Volatile Anesthetic Concentrations during the Maintenance Phase of Anesthesia in the B-Unaware Trial. Anesthesiology, 2011, 115, 1209-1218.	2.5	117
59	Memories and Dreams. Anesthesiology, 2011, 115, 1147-1148.	2,5	1
60	Isoflurane-induced Neuroapoptosis in the Neonatal Rhesus Macaque Brain: Isoflurane or Ischemia-Reperfusion?. Anesthesiology, 2010, 113, 1245-1246.	2.5	4
61	Neurosteroid analogues. 15. A comparative study of the anesthetic and GABAergic actions of alphaxalone, î"16-alphaxalone and their corresponding 17-carbonitrile analogues. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6680-6684.	2.2	15
62	Postoperative Cognitive Decline: The Unsubstantiated Phenotype. Anesthesiology, 2010, 113, 1246-1248.	2.5	6
63	Cognitive Decline after Surgery and Illness. Anesthesiology, 2010, 112, 1283-1285.	2.5	3
64	Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids. Current Neuropharmacology, 2010, 8, 18-25.	2.9	21
65	A Synthetic 18-Norsteroid Distinguishes between Two Neuroactive Steroid Binding Sites on GABA <sub>A</sub> Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 404-413.	2.5	22
66	Isoflurane-induced Neuroapoptosis in the Neonatal Rhesus Macaque Brain. Anesthesiology, 2010, 112, 834-841.	2.5	560
67	Leadership in Postgraduate Medical Education. Anesthesiology, 2010, 113, 754-754.	2.5	0
68	Photodynamic Effects of Steroid-Conjugated Fluorophores on GABA <sub>A</sub> Receptors. Molecular Pharmacology, 2009, 76, 754-765.	2.3	3
69	Performance of Certified Registered Nurse Anesthetists and Anesthesiologists in a Simulation-Based Skills Assessment. Anesthesia and Analgesia, 2009, 108, 255-262.	2.2	43
70	The influence of the membrane on neurosteroid actions at GABAA receptors. Psychoneuroendocrinology, 2009, 34, S59-S66.	2.7	44
71	Long-term Cognitive Decline in Older Subjects Was Not Attributable to Noncardiac Surgery or Major Illness. Anesthesiology, 2009, 111, 964-970.	2.5	161
72	Potential of xenon to induce or to protect against neuroapoptosis in the developing mouse brain. Canadian Journal of Anaesthesia, 2008, 55, 429-436.	1.6	84

#	Article	IF	CITATIONS
73	Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens. European Journal of Medicinal Chemistry, 2008, 43, 107-113.	5.5	30
74	Anesthesia Awareness and the Bispectral Index. New England Journal of Medicine, 2008, 358, 1097-1108.	27.0	847
75	Neurosteroid Analogues. 14. Alternative Ring System Scaffolds: GABA Modulatory and Anesthetic Actions of Cyclopenta[b]phenanthrenes and Cyclopenta[b]anthracenes. Journal of Medicinal Chemistry, 2008, 51, 1309-1318.	6.4	11
76	Ethanol Modulates the Interaction of the Endogenous Neurosteroid Allopregnanolone with the $\hat{1}\pm1\hat{1}^22\hat{1}^3$ 2L GABAA Receptor. Molecular Pharmacology, 2007, 71, 461-472.	2.3	16
77	Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 709-720.	2.5	238
78	Anticonvulsant and anesthetic effects of a fluorescent neurosteroid analog activated by visible light. Nature Neuroscience, 2007, 10, 523-530.	14.8	21
79	Mechanisms of neurosteroid interactions with GABAA receptors., 2007, 116, 35-57.		136
80	Can We Get There if We Don't Know Where We're Going?. Anesthesiology, 2007, 106, 651-652.	2.5	16
81	Performance of Residents and Anesthesiologists in a Simulation-based Skill Assessment. Anesthesiology, 2007, 107, 705-713.	2.5	123
82	Neurosteroid Analogues. 11. Alternative Ring System Scaffolds:  γ-Aminobutyric Acid Receptor Modulation and Anesthetic Actions of Benz[f]indenes. Journal of Medicinal Chemistry, 2006, 49, 4595-4605.	6.4	13
83	Intrapatient Reproducibility of the BISxp® Monitor. Anesthesiology, 2006, 104, 242-248.	2.5	56
84	Impact of Anesthesia Management Characteristics on Severe Morbidity and Mortality: Are We Convinced?. Anesthesiology, 2006, 104, 204-204.	2.5	3
85	Neurosteroid Analogues. 10. The Effect of Methyl Group Substitution at the C-6 and C-7 Positions on the GABA Modulatory and Anesthetic Actions of $(3\hat{l}\pm,5\hat{l}\pm)$ - and $(3\hat{l}\pm,5\hat{l}^2)$ -3-Hydroxypregnan-20-one. Journal of Medicinal Chemistry, 2005, 48, 3051-3059.	6.4	19
86	Selective Antagonism of 5α-Reduced Neurosteroid Effects at GABAA Receptors. Molecular Pharmacology, 2004, 65, 1191-1197.	2.3	81
87	Neuroactive Steroid Interactions with Voltage-Dependent Anion Channels: Lack of Relationship to GABAA Receptor Modulation and Anesthesia. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 502-511.	2.5	34
88	Neuroactive steroids have multiple actions to potentiate GABAAreceptors. Journal of Physiology, 2004, 558, 59-74.	2.9	76
89	Isoflurane Inhibits Transmitter Release and the Presynaptic Action Potential. Anesthesiology, 2004, 100, 663-670.	2.5	136
90	Neurosteroid Analogues. 9. Conformationally Constrained Pregnanes:  Structureâ^'Activity Studies of 13,24-Cyclo-18,21-dinorcholane Analogues of the GABA Modulatory and Anesthetic Steroids (3α,5α)- and (3α,5β)-3-Hydroxypregnan-20-one. Journal of Medicinal Chemistry, 2003, 46, 5334-5348.	6.4	31

#	Article	IF	CITATIONS
91	Photoaffinity Labeling with a Neuroactive Steroid Analogue. Journal of Biological Chemistry, 2003, 278, 13196-13206.	3.4	70
92	Postoperative Cognitive Dysfunction: Overinterpretation of Data?. Anesthesiology, 2003, 98, 1294-1295.	2.5	1
93	Mervyn Maze, M.B., Ch.B., F.R.C.P Anesthesiology, 2003, 99, 777-778.	2.5	1
94	MANAGEMENT OF THE POSTPUBERTAL PATIENT WITH CRYPTORCHIDISM: AN UPDATED ANALYSIS. Journal of Urology, 2002, 167, 1329-1333.	0.4	35
95	Recent developments in structure–activity relationships for steroid modulators of GABAA receptors. Brain Research Reviews, 2001, 37, 91-97.	9.0	73
96	Relevant Concentrations of Inhaled Anesthetics for In Vitro Studies of Anesthetic Mechanisms. Anesthesiology, 2001, 94, 915-921.	2.5	49
97	Steroid Inhibition of Rat Neuronal Nicotinic $\hat{l}\pm4\hat{l}^22$ Receptors Expressed in HEK 293 Cells. Molecular Pharmacology, 2000, 58, 341-351.	2.3	73
98	Neurosteroid Analogues. 8. Structure $\hat{a}$ Activity Studies of N-Acylated 17a-Aza-D-homosteroid Analogues of the Anesthetic Steroids ( $3\hat{i}\pm$ , $5\hat{i}\pm$ )- and ( $3\hat{i}\pm$ , $5\hat{i}^2$ )-3-Hydroxypregnan-20-one. Journal of Medicinal Chemistry, 2000, 43, 3201-3204.	6.4	24
99	Postanesthesia Care Unit Length of Stay. Anesthesia and Analgesia, 1998, 87, 628-633.	2.2	78
100	Neurosteroid analogues. Part 5.1 Enantiomers of neuroactive steroids and benz[e]indenes: total synthesis, electrophysiological effects on GABAA receptor function and anesthetic actions in tadpoles. Journal of the Chemical Society Perkin Transactions 1, 1997, , 3665-3672.	0.9	32
101	Protamine relaxes vascular smooth muscle by directly reducing cytosolic free calcium concentrations in small resistance arteries. Journal of Anesthesia, 1996, 10, 252-259.	1.7	6
102	Volatile Anesthetic Effects on Inositol Trisphosphate-Gated Intracellular Calcium Stores in GH3 Cells. Advances in Pharmacology, 1994, 31, 343-350.	2.0	3
103	Direct observation of a fluorinated anticonvulsant in brain tissue using 19F-NMR techniques. Biochemical Pharmacology, 1993, 45, 949-959.	4.4	1
104	Fluorine-19 NMR spin-spin relaxation (T2) method for characterizing volatile anesthetic binding to proteins. Analysis of isoflurane binding to serum albumin. Biochemistry, 1992, 31, 7069-7076.	2.5	80
105	The Action of Halothane on Stimulus-Secretion Coupling in Clonal (GH3) Pituitary Cells. Annals of the New York Academy of Sciences, 1991, 625, 293-295.	3.8	1
106	19F-Nuclear Magnetic Resonance Spectroscopy Annals of the New York Academy of Sciences, 1991, 625, 725-732.	3.8	7
107	Anion exchange chromatographic separation of inositol phosphates and their quantification by gas chromatography. Analytical Biochemistry, 1989, 176, 109-116.	2.4	29
108	Isoflurane Uptake and Elimination Are Delayed by Absorption of Anesthetic by the Scimed Membrane Oxygenator. Anesthesia and Analgesia, 1989, 69, 657???662.	2.2	22

#	Article	IF	CITATIONS
109	ANESTHESIA AND CHEMICAL SECOND MESSENGER GENERATION IN THE ADRENERGIC NERVOUS SYSTEM. International Anesthesiology Clinics, 1989, 27, 234-247.	0.8	O
110	Altered phosphoinositide fatty acid composition, mass and metabolism in brain essential fatty acid deficiency. Lipids and Lipid Metabolism, 1988, 960, 54-60.	2.6	11
111	The potency of fluorinated ether anesthetics correlates with their 19F spin-spin relaxation times in brain tissue. Biochemical and Biophysical Research Communications, 1988, 151, 1039-1045.	2.1	17
112	A Saturable Halothane Binding Site in Rat Brain Described by 19F-NMR. Annals of the New York Academy of Sciences, 1987, 508, 429-431.	3.8	1
113	Correlation between the anaesthetic effect of halothane and saturable binding in brain. Nature, 1987, 328, 157-160.	27.8	87
114	Essential fatty acid deficiency: A new look at an old problem. Prostaglandins, Leukotrienes, and Medicine, 1986, 23, 123-127.	0.7	9
115	A unique cardiac cytosolic acyltransferase with preferential selectivity for fatty acids that form cyclooxygenase/lipoxygenase metabolites and reverse essential fatty acid deficiency. Lipids and Lipid Metabolism, 1985, 836, 267-273.	2.6	24
116	Differential responses of two carboxylases from Euglena to the state of chloroplast development. FEBS Letters, 1974, 46, 233-235.	2.8	7
117	G-protein-coupled receptors., 0,, 17-27.		0
118	Ion channels. , 0, , 28-46.		0
119	Other signaling pathways. , 0, , 47-56.		0
120	Principles of pharmacokinetics. , 0, , 57-71.		0
121	Drug transport and transporters. , 0, , 90-102.		0
122	Target-controlled infusions and closed-loop administration. , 0, , 103-122.		1
123	Alternative routes of drug administration. , 0, , 123-131.		0
124	Principles of pharmacogenetics., 0,, 132-146.		0
125	Pharmacoeconomics., 0,, 166-176.		0
126	Synaptic transmission. , 0, , 192-209.		0

#	Article	IF	CITATIONS
127	Memory, learning, and cognition. , 0, , 210-226.		O
128	Mechanisms of pain transmission and transduction., 0,, 227-247.		1
129	The generation and propagation of action potentials. , 0, , 248-260.		O
130	Neuromuscular function., 0,, 261-276.		1
131	Vascular reactivity., 0,, 277-292.		0
132	Cardiac rhythm. , 0, , 293-315.		0
133	Myocardial performance., 0,, 316-329.		O
134	Autonomic function., 0,, 330-344.		0
135	Immunity and inflammation. , 0, , 345-358.		0
136	Clinical pharmacology of inhaled anesthetics. , 0, , 397-419.		2
137	Pharmacokinetics of intravenous anesthetics. , 0, , 420-443.		1
138	Alpha2-agonists and other sedatives and amnestics., 0,, 478-492.		0
139	Mechanisms of action of opioids. , 0, , 493-508.		2
140	Pharmacokinetics of opioids., 0,, 509-530.		2
141	Clinical pharmacology of opioids. , 0, , 531-547.		2
142	Nonsteroidal anti-inflammatory drugs. , 0, , 548-562.		0
143	Other ion-channel and receptor ligands for analgesia. , 0, , 563-573.		O
144	Antiepileptic and antipsychotic drugs., 0,, 589-607.		0

#	Article	IF	CITATIONS
145	Neuromuscular blocking drugs. , 0, , 608-632.		O
146	Drugs for reversal of neuromuscular blockade., 0,, 633-647.		0
147	Sympathomimetic and sympatholytic drugs. , 0, , 648-665.		0
148	Parasympathomimetic and parasympatholytic drugs., 0,, 666-675.		1
149	Beta-blockers and other adrenoceptor antagonists. , 0, , 676-688.		0
150	Antiarrhythmic drugs., 0,, 689-705.		0
151	Vasodilators. , 0, , 724-740.		0
152	Calcium channel blockers. , 0, , 741-750.		0
153	Pulmonary vasodilators. , 0, , 767-782.		0
154	Fluids and electrolytes., 0,, 800-813.		0
155	Corticosteroids and anti-inflammatory drugs. , 0, , 814-829.		0
156	Antirejection drugs and immunosuppressants. , 0, , 830-841.		1
157	Antiemetics. , 0, , 855-873.		1
158	Insulin and antihyperglycemic drugs. , 0, , 874-889.		0
159	Nutritional pharmacology. , 0, , 890-911.		0
160	Obstetric pharmacology. , 0, , 948-962.		0
161	Antimicrobial therapy. , 0, , 963-986.		0
162	Induction of anesthesia. , 0, , 1007-1026.		3

#	Article	IF	CITATIONS
163	Maintenance of and emergence from anesthesia. , 0, , 1027-1040.		O
164	Management of sedation, analgesia, and delirium., 0,, 1041-1060.		0
165	Postoperative analgesia., 0,, 1061-1076.		O
166	Control of blood pressure and vascular tone., 0,, 1077-1090.		0
167	Cardiac protection and pharmacologic management of myocardial ischemia., 0,, 1091-1105.		O
168	Management of patients with chronic alcohol or drug use. , 0, , 1106-1116.		0
169	Pediatric pharmacology. , 0, , 1128-1138.		O
170	Geriatric pharmacology. , 0, , 1139-1150.		0
171	Emerging concepts of anesthetic neuroprotection and neurotoxicity., 0,, 1151-1162.		O
172	Renal protection and pharmacology. , 0, , 783-799.		0
173	Positive inotropic drugs. , 0, , 706-723.		O